Correction: Association of clinical, laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors – rationale and design of the “Beyond-SMuRFs Study”

Moysidis, Dimitrios V.; Daios, Stylianos; Anastasiou, Vasileios; Liatsos, Alexandros; Papazoglou, Αndreas S.; Karagiannidis, Efstratios; Kamperidis, Vasileios; Makedou, Kali; Thisiadou, Aikaterini; Karalazou, Paraskevi; Papadakis, Marios; Savopoulos, Christos; Ziakas, Antonios; Giannakoulas, George; Vassilikos, Vassilios; Γιαννόπουλος, Γεώργιος

doi:10.1186/s12872-023-03243-6

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic roles and associations of these parameters will be assessed in this study. Furthermore, the integration of artificial intelligence techniques may facilitate the development of clinically significant polygenic risk scores [39,40], thereby offering potential advancements in risk prediction and patient management.…”

Section: Discussion and Expected Resultsmentioning

confidence: 99%

Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’

Daios,

Anastasiou,

Moysidis

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Acute myocardial infarction (AMI) remains a major cause of death worldwide. Survivors of AMI are particularly at high risk for additional cardiovascular events. Consequently, a comprehensive approach to secondary prevention is necessary to mitigate the occurrence of downstream complications. This may be achieved through a multiparametric tailored risk stratification by incorporating clinical, laboratory and echocardiographic parameters. Methods: The ‘‘CLEAR-AMI Study’’ (ClinicalTrials.gov Identifier: NCT05791916) is a non-interventional, prospective study including consecutive patients with AMI without a known history of coronary artery disease. All patients satisfying these inclusion criteria are enrolled in the present study. The rationale of this study is to refine risk stratification by using clinical, laboratory and novel echocardiographic biomarkers. All the patients undergo a comprehensive transthoracic echocardiographic assessment, including strain and myocardial work analysis of the left and right heart chambers, within 48 h of admission after coronary angiography. Their laboratory profile focusing on systemic inflammation is captured during the first 24 h upon admission, and their demographic characteristics, past medical history, and therapeutic management are recorded. The angioplasty details are documented, the non-culprit coronary lesions are archived, and the SYNTAX score is employed to evaluate the complexity of coronary artery disease. A 24-month follow-up period will be recorded for all patients recruited. Conclusion: The ‘‘CLEAR-AMI” study is an ongoing prospective registry endeavoring to refine risk assessment in patients with AMI without a known history of coronary artery disease, by incorporating echocardiographic parameters, biochemical indices, and clinical and coronary characteristics in the acute phase of AMI.

show abstract

Section: Discussion and Expected Resultsmentioning

confidence: 99%